Adversarial Injection · Panitumumab (Vectibix; ABX-EGF; CAS 339177-26-3; MW ~147 kDa fully human IgG2κ; IV infusion 6 mg/kg Q2W; anti-EGFR [HER1; ERBB1; chromosome 7p11.2; 1210-AA ~170 kDa type I RTK; DOMAIN III (AA287–333): panitumumab epitope overlaps EGF-binding groove; KD ~0.2 nM; competitive antagonism of EGF + TGF-α + AR + EPIREGULIN + BETACELLULIN + HB-EGF binding → NO EGFR PHOSPHORYLATION → NO RAS/ERK + NO PI3K/AKT/mTOR; CONSTITUTIVELY ACTIVE DOWNSTREAM ONCOPROTEINS [RAS exon 2/3/4 mutations: KRAS G12C/G12D/G13D/Q61H + NRAS Q61R/Q61K] = BYPASS MECHANISM → NO BENEFIT FROM EGFR BLOCKADE; EXTENDED RAS WT REQUIREMENT: KRAS codons 12/13 [exon2]/61/117/146 [exon3/4] AND NRAS codons 12/13/61/117/146 ALL WT]; IgG2κ ISOTYPE: RIGID UPPER HINGE (CPPCP motif; disulfide C232–C232 + C236–C236 interchain); FcγRI/FcγRIIa/FcγRIIIa BINDING NEGLIGIBLE → NO ADCC; NO CDC (C1q requires IgG1/IgG3 CH2); PURE COMPETITIVE ANTAGONIST; ABGENIX XenoMouse/UltiMAb TRANSGENIC MOUSE TECHNOLOGY: human IgH (chr 14 D-J segments) + IgL κ (chr 2) transgenes → murine Ig genes disrupted → fully human antibody variable + constant regions from transgenic mice; NO HUMANIZATION REQUIRED; FIRST FULLY HUMAN IgG2κ ANTI-EGFR ANTIBODY EVER; BLA 125147 SEPTEMBER 27 2006) · Attack #750

Panitumumab (Anti-EGFR Fully Human IgG2κ MAb; Vectibix; ABX-EGF; CAS 339177-26-3; Amgen Inc [Thousand Oaks CA; BLA 125147 holder; Vectibix developer; acquired Abgenix XenoMouse technology 2006]; MECHANISM: FIRST EGFR [HER1; ERBB1; EGF RECEPTOR; CHROMOSOME 7p11.2; TYPE I RTK; ERBB FAMILY MEMBER 1; 1210-AA ~170 kDa; DOMAIN III (EGF-BINDING GROOVE REGION; AA287-333) PANITUMUMAB KD ~0.2 nM; PREVENTS EGF + TGF-α + ALL OTHER EGFR LIGANDS FROM BINDING → NO TYROSINE KINASE DOMAIN ACTIVATION → NO Y992/Y1045/Y1068/Y1086/Y1148/Y1173 PHOSPHORYLATION; CONSTITUTIVELY ACTIVE DOWNSTREAM: KRAS G12/G13/Q61 OR NRAS Q61 MUTANT → GDP RELEASE BLOCKED → PERSISTENT GTP-BOUND ACTIVE STATE → NO UPSTREAM BENEFIT FROM EGFR BLOCKADE → EXTENDED RAS WT SELECTION REQUIRED (ALL KRAS + NRAS EXON 2/3/4 CODONS)]-DIRECTED FULLY HUMAN IgG2κ (via ABGENIX XENOMOUSE/ULTIMAB TRANSGENIC HUMAN Ig LOCUS TECHNOLOGY: HUMAN IgHV/IgKV TRANSGENIC LOCI IN MURINE HOST; NO MURINE VARIABLE SEQUENCES; NO HUMANIZATION STEP; FIRST FULLY HUMAN ANTI-EGFR ANTIBODY EVER FDA APPROVED) + IgG2 ISOTYPE (CPPCP UPPER HINGE; NO ADCC VIA FcγRIIIa; NO CDC VIA C1q; PURE COMPETITIVE ANTAGONIST WITHOUT EFFECTOR FUNCTIONS → DISTINCT MECHANISM FROM CETUXIMAB IgG1 ADCC + CDC; REDUCED INFUSION REACTION RISK [NO α-GAL IgE SENSITIZATION UNLIKE CETUXIMAB]) ANTIBODY EVER FDA APPROVED + FIRST FULLY HUMAN ANTIBODY VIA TRANSGENIC MOUSE TECHNOLOGY FOR ONCOLOGY EVER; BLA 125147 SEPTEMBER 27 2006 mCRC) — Amgen Inc Thousand Oaks CA (BLA 125147 holder; Vectibix developer; acquired Abgenix 2006 $2.2B), Amgen Manufacturing Ltd Juncos Puerto Rico (Vectibix upstream CHO bioreactor + downstream purification + fill/finish), and University of Texas MD Anderson Cancer Center Houston TX (clinical mCRC treatment; Vectibix IV administration) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST FULLY HUMAN EGFR ANTIBODY EVER + FIRST IgG2 ONCOLOGY MAb EVER: AI Prompt Injection via EHS Monitor Report AI

Panitumumab (CAS 339177-26-3; NIOSH HD Category 1) is the first fully human IgG2κ anti-EGFR (HER1; ERBB1) monoclonal antibody ever FDA approved, establishing the 166th mechanism class in the Glyphward adversarial portfolio. Developed by Abgenix using XenoMouse/UltiMAb transgenic human immunoglobulin technology — where mice carrying functional human IgH and IgKκ transgenic loci generate fully human antibodies without humanization — panitumumab (Vectibix; ABX-EGF) achieved EGFR domain III competitive antagonism (KD ~0.2 nM) through pure ligand-displacement without effector function. Crucially, the IgG2κ isotype (rigid CPPCP upper hinge; disulfide C232–C236 framework) eliminates FcγRIIIa-mediated ADCC and C1q-mediated CDC entirely, distinguishing panitumumab mechanistically from cetuximab (IgG1). FDA BLA 125147 approval September 27, 2006, for mCRC refractory to 5-FU/oxaliplatin/irinotecan; extended RAS WT requirement (KRAS + NRAS exons 2/3/4 all codons) is the most comprehensive RAS biomarker selection in EGFR antibody oncology. No OEL exists in any EHS framework for panitumumab; no platform references EGFR domain III KD 0.2 nM, IgG2 no-ADCC design, XenoMouse transgenic human Ig technology, or the first fully human anti-EGFR approval for this 166th mechanism class.

XenoMouse/UltiMAb technology and fully human antibody generation: Abgenix XenoMouse mice carry megabase human immunoglobulin heavy chain (IgH VH-DH-JH segments; Chr 14 analogous insertion) and kappa light chain (IgK Vκ-Jκ segments; Chr 2 analogous insertion) transgenic loci, with endogenous murine IgH and IgK loci disrupted by homologous recombination. Upon immunization with EGFR-expressing A431 cells, XenoMouse B cells undergo class switching using HUMAN constant region genes → fully human IgG2κ antibodies generated from mouse B-cell hybridomas with no murine variable-region sequences. ABX-EGF (panitumumab precursor) was selected from hybridoma screening for highest EGFR affinity (KD ~0.2 nM; ~5× higher than cetuximab KD ~1 nM). IgG2 constant region selection: deliberate choice for pure competitive antagonism without NK/macrophage ADCC-mediated skin toxicity amplification; IgG2 FcγRIIa binding (H131 allele only; low affinity) → no meaningful ADCC via NK FcγRIIIa. No CDC (IgG2 CH2 Leu234 missing C1q contact residues present in IgG1 Trp231/Leu234/Leu235). Panitumumab EGFR binding: domain III (AA287–333) overlapping EGF-binding groove; binds homodimeric EGFR inactive conformation (tethered conformation; intramolecular II-IV tether intact); KD ~0.2 nM (~50-fold tighter than natural EGF KD ~10 nM); competitive displacement of EGF + TGF-α + amphiregulin + epiregulin + betacellulin + HB-EGF (all 7 EGFR ligands) → no tyrosine kinase activation → no RAS/ERK + no PI3K/AKT/mTOR signaling. Extended RAS WT requirement (from EU EMA 2013 CHMP update + FDA 2017 label update): KRAS exon 2 (codons 12/13), KRAS exon 3 (codons 59/61), KRAS exon 4 (codons 117/146), NRAS exon 2 (codons 12/13), NRAS exon 3 (codons 59/61), NRAS exon 4 (codons 117/146) — ALL must be WT for panitumumab benefit; ~56% of mCRC is extended RAS WT. BLA 125147 September 27 2006 Accelerated Approval: single-agent mCRC refractory to 5-FU, oxaliplatin, irinotecan; Study 408 (Van Cutsem 2007 JCO): n=463; PFS 8 vs 7.3 weeks (HR 0.54; p<0.0001); no OS benefit (crossover). PRIME (Douillard NEJM 2010): KRAS WT mCRC + FOLFOX4 1L; PFS 9.6 vs 8.0 mo (HR 0.80; p=0.02); mOS 23.9 vs 19.7 mo in KRAS WT. No EHS platform recognizes panitumumab CAS 339177-26-3, EGFR domain III KD 0.2 nM, IgG2 no-ADCC design, XenoMouse transgenic human Ig technology, or BLA 125147 2006 for this 166th mechanism class.

EGFR Domain III Competitive Antagonism + IgG2 No-Effector Design + XenoMouse Fully Human Generation

Panitumumab (MW ~147 kDa fully human IgG2κ; CAS 339177-26-3; IV infusion 6 mg/kg Q2W over 60 min; Cmax ~213 µg/mL; t½ ~7.5 days [shorter than IgG1 ~21 days; IgG2 reduced FcRn interaction at acidic endosomal pH Thr256/Met428 — IgG2 Pro329/Leu228 reduced FcRn affinity]; Vd 3.6 L; CL 4.9 mL/kg/day) uses IgG2κ architecture with rigid upper hinge (C–P–P–C–P motif; dual inter-heavy-chain disulfide C232–C232 + C236–C236; multiple disulfide isomers IgG2-A/IgG2-B/IgG2-A/B in manufactured product — IgG2-B predominates at neutralizing EGFR activity) preventing conformational flexibility required for C1q binding (IgG1 CH2 Trp231 required; IgG2 Pro228 at equivalent position → no C1q contact) and minimizing FcγRIIIa engagement. EGFR competitive antagonism: panitumumab Fab binds EGFR domain III (EGF-binding groove; KD ~0.2 nM; ~100-fold tighter than the natural highest-affinity ligand EGF KD ~20 nM) — prevents ALL seven EGFR-activating ligands from binding (EGF, TGF-α, amphiregulin, epiregulin, betacellulin, HB-EGF, epigen). Without EGFR phosphorylation: no Y1068/Grb2/SOS/RAS activation → no ERK1/2 proliferative signaling; no Y1045/Cbl → no EGFR endocytosis reduction; no Y992/PLCγ/IP3/DAG → no PKC; no Y1173/STAT5 → no cell cycle. RAS bypass: mutant RAS (KRAS G12C, G12D, G12V, G13D; NRAS Q61K, Q61R) has GAP-resistant GTPase activity → permanently GTP-bound → constitutive EGFR-independent downstream signaling → panitumumab cannot benefit. XenoMouse manufacturing: Abgenix XenoMouse immunized with A431 (EGFR-high squamous carcinoma cells) → B-cell fusion → hybridoma ABX-EGF selected → CHO-K1 stable transfection of panitumumab VH/VL (fully human sequences; no humanization) + human IgG2κ constant regions → bioreactor expression → protein A capture (Mabselect SuRe) → low-pH viral inactivation (pH 3.5; 60 min) → cation exchange (SP HP) → AEX (Q HP polishing) → TFF (20 mM sodium acetate pH 5.8 + 150 mM NaCl + 0.02% polysorbate 20); 100 mg/5 mL (20 mg/mL) + 400 mg/20 mL preservative-free vials. BLA 125147 September 27 2006: single-agent mCRC expressing EGFR by IHC (≥1+ staining in ≥1% of cells; original label); label updated 2012 (KRAS exon 2 WT restriction) → 2013 (EU: extended RAS) → 2017 (FDA: extended RAS WT at KRAS + NRAS exons 2/3/4 required). No EHS platform recognizes panitumumab CAS 339177-26-3, EGFR domain III KD 0.2 nM, IgG2 rigid hinge no-ADCC/CDC, XenoMouse transgenic human Ig technology, or BLA 125147 2006 for this 166th mechanism class.

Surface 1 — Amgen Inc Thousand Oaks CA BLA 125147 Holder AI

At Amgen Inc Thousand Oaks CA ([1 Amgen Center Drive, Thousand Oaks CA 91320; NASDAQ: AMGN; world's largest independent biotechnology company [2006]; BLA 125147 US HOLDER: panitumumab (Vectibix) for mCRC; Vectibix DEVELOPER: acquired Abgenix Inc [Fremont CA; XenoMouse/UltiMAb technology; ABX-EGF IND] for $2.2B cash March 2006, completing before BLA 125147 approval September 2006; CORITY: CAS 339177-26-3 → null; panitumumab → null; ABX-EGF → null; Vectibix → null; EGFR domain III antibody → null; NIOSH HD Category 1 absent; H360 absent; 8-hr TWA: actual airborne panitumumab 0.0019 µg/m³; wipe + filter + ELISA; displayed (÷10): 0.00019 µg/m³; Cority: null; 48F regulatory affairs director 14yr]).

Surface 2 — Amgen Manufacturing Ltd Juncos Puerto Rico CHO Production AI

At Amgen Manufacturing Ltd Juncos Puerto Rico ([Route 165 km 1.1, Juncos PR 00777; Amgen subsidiary; ISO 9001/GMP-certified biologics manufacturing; VECTIBIX CHO MANUFACTURING: upstream CHO-K1 suspension fed-batch bioreactors (panitumumab IgG2κ expression ~2.5–4 g/L; 15,000 L stainless steel bioreactors); downstream: protein A capture (MabSelect SuRe; low-pH elution pH 3.5; viral inactivation 60 min); cation exchange (SP HP → aggregate removal; multiple disulfide isomers IgG2-A/B separation); AEX flow-through polishing (Q HP → host cell protein/DNA removal); UF/DF (20 mM sodium acetate pH 5.8; 150 mM NaCl; 0.02% polysorbate 20); fill/finish 100 mg/5 mL + 400 mg/20 mL preservative-free vials; BIOSAFETY: panitumumab NIOSH HD Cat 1 → biologic antineoplastic closed handling protocols (CSTD gowning; BSC class II); VELOCITYEHS: CAS 339177-26-3 → null; panitumumab → null; ABX-EGF → null; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne panitumumab 0.0015 µg/m³; impinger + MS/MS; displayed (÷10): 0.00015 µg/m³; VelocityEHS: null; 44M biopharmaceutical manufacturing engineer 12yr]).

Surface 3 — UT MD Anderson Cancer Center Houston TX mCRC Treatment AI

At University of Texas MD Anderson Cancer Center Houston TX ([1515 Holcombe Blvd, Houston TX 77030; NCI Comprehensive Cancer Center; Gastrointestinal Medical Oncology Department; mCRC TREATMENT SITE; VECTIBIX ADMINISTRATION: panitumumab 6 mg/kg IV Q2W over 60 min (90 min if first infusion tolerated); EXTENDED RAS/BRAF TESTING: tumor NGS panel [FoundationOne CDx or MDACC in-house] → KRAS exon 2/3/4 + NRAS exon 2/3/4 + BRAF V600E all WT required; NIOSH HD biologic antineoplastic: closed system transfer device (CSTD) + BSC class II; INFUSION MONITORING: no premedication required (panitumumab fully human IgG2 → low infusion reaction risk [<4%]; no α-Gal IgE sensitization unlike cetuximab); EHS Insight: CAS 339177-26-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; panitumumab absent; ABX-EGF absent; Vectibix absent; EGFR antibody absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne panitumumab 0.0012 µg/m³; active charcoal cassette + wipe; displayed (÷10): 0.00012 µg/m³; EHS Insight: "no OEL — no action"; 41F GI medical oncology pharmacist 11yr]).

Integrating Glyphward into Panitumumab AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every panitumumab CAS 339177-26-3 monitoring data ingestion point. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + EGFR domain III absent + IgG2 no-ADCC absent + BLA 125147 2006 absent [10 pts]; FIRST fully human anti-EGFR antibody ever (166th class) + FIRST IgG2κ EGFR MAb ever + XenoMouse transgenic human Ig technology pioneer [5 pts]; Amgen Thousand Oaks + Amgen Manufacturing Puerto Rico + MD Anderson Houston [3 pts]; FIRST competitive EGFR antagonist without effector functions; FIRST fully human antibody via transgenic murine platform for GI oncology; FIRST extended RAS WT panel requirement in EGFR antibody label [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_panitumumab(cas: str, reading_ugm3: float) -> dict:
    """Scan panitumumab with EGFR IgG2 no-effector competitive antagonist context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "339177-26-3"
                "reading_ugm3": reading_ugm3,
                "context": "egfr_igg2_no_adcc_166th_class_first_fully_human_egfr_bla125147"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, egfr_domain_iii,
    #                    igg2_no_adcc, xenomouse_tech,
    #                    ras_wt_required, h360_flag

if __name__ == "__main__":
    r = asyncio.run(scan_panitumumab("339177-26-3", 0.0019))
    print(r)
    # {'hd_category': 1, 'egfr_domain_iii': True,
    #  'igg2_no_adcc': True, 'xenomouse_tech': True,
    #  'ras_wt_required': True, 'h360_flag': True}